Maintenance therapy after remission for acute myeloid leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether adding venetoclax to azacitidine after a patient reaches remission helps keep the leukemia from coming back. It is for people with acute myeloid leukemia (AML) who have completed initial treatment and are in their first remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with acute myeloid leukemia (AML) or a related condition called MDS/AML.
- You are between 14 and 74 years old.
- You have finished initial treatment and are in your first complete remission (no signs of leukemia).
- You have received at least two cycles of a standard chemotherapy drug called cytarabine at a certain dose.
- You have no signs of leukemia in your spinal fluid (central nervous system).
- You have not had a stem cell transplant in the past and do not plan to have one within the next 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests whether azacitidine (CC-486) plus venetoclax can help people with acute myeloid leukemia (AML) that is not APL. It’s designed to find safe dosing and see how well the combination works for newly diagnosed or relapsed/refractory AML.
This trial studies azacytidine (AZA) plus venetoclax as maintenance treatment to help keep acute myeloid leukemia (AML) in first remission. It may help delay or prevent AML from returning in younger adults who cannot get a stem cell transplant right away.
This trial tests a combination of two drugs, azacitidine and venetoclax, for people with acute myeloid leukemia (AML) who have achieved remission after initial chemotherapy but still have tiny amounts of leukemia cells left (measurable residual disease). The goal is to see if this treatment can clear those remaining cells before a stem cell transplant.
This trial tests whether taking venetoclax can help keep your leukemia from coming back after you reach complete remission. It is for patients who are not able to get a bone marrow transplant right away.
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
This Phase 1 trial studies whether a combination of venetoclax (ABT-199) and “purine analogues” can help adults with AML that has come back or didn’t respond to earlier treatment. It’s designed to test safety and early effectiveness in people who haven’t previously developed resistance to venetoclax.
Hear when a new AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.